Vinge advised Calliditas Therapeutics on the deal. Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas...
You must be a Standard 1 Year member to access this content.
Vinge advised Hansa Biopharma AB on the deal. Hansa Biopharma AB (publ) finalized a directed share issue through which the company raises proceeds of SEK 372 million...
You must be a Standard 1 Year member to access this content.
Vinge advised Vimian Group AB on the offering. Vimian Group AB (publ) partly guaranteed rights issue which will provide Vimian with issue proceeds of SEK 1,633...
You must be a Standard 1 Year member to access this content.
Vinge advised Norvestor on the deal. Norvestor VI L.P received a public offer by Altor PC AB to the shareholders of Permascand Top Holding AB (publ). Norvestor holds...
You must be a Standard 1 Year member to access this content.
Vinge and Cravath Swaine & Moore advised Thermo Fisher Scientific Inc. on the deal, Ropes & Gray advised Summa Equity AB, Baker McKenzie advised Olink, Debevoise...
You must be a Standard 1 Year member to access this content.
Vinge advised EQT IX on the deal. EQT IX completed the sale of shares in Beijer Ref AB (publ) through an accelerated bookbuilding. In total, 40...
You must be a Standard 1 Year member to access this content.
Vinge advised Symrise on the deal. Symrise AG has made a public mandatory bid for all shares in Swedencare AB (publ). The offer values all shares in...
You must be a Standard 1 Year member to access this content.
Vinge acted for Xspray Pharma in connection with its rights issue of units. Through the rights issue of units, Xspray (STO:XSPRAY) is expected to receive approximately SEK 300...
You must be a Standard 1 Year member to access this content.
Vinge advised François-Charles Oberthur on the deal, while Delphi advised Rolling Optics. François-Charles Oberthur SAS announced a cash offer to the holders of ordinary shares, preference shares,...
You must be a Standard 1 Year member to access this content.
Vinge has advised Oncopeptides on the deal. Wigge & Partners advised the European Investment Bank (EIB). The loan agreement with the European Investment Bank (EIB) grants...
You must be a Standard 1 Year member to access this content.
Vinge advised Vimian on the deal. Vimian completed a directed share issue of approximately MSEK 1,500, before issue costs. The share issue is in part based on...
You must be a Standard 1 Year member to access this content.
Vinge advised Oncopeptides on the deal. The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds...
You must be a Standard 1 Year member to access this content.
